Yes, to my knowledge, I think he still feels the same way. He does not like JJ's high number of PRs. I asked another guy to take a look and he was highly concerned about AEMD' having "one" product and how broke they are.
I think for alot of stock people that take quick looks, even biotech stock people, I do not think they grasp how revolutionary our technology is likely to be and how many different medical and scientific applications could well arise.
News 
Market Data 
Discover 
AI
